1. [1] Payne K, Annemans L. Reflections on market access for personalized medicine: recommendations for Europe. Value Health 2013; 16: S32-S38. [DOI:10.1016/j.jval.2013.06.010] [PMID]

2. [2] Janiaud P, Serghiou S, Ioannidis JP. New clinical trial designs in the era of precision medicine: an overview of definitions, strengths, weaknesses, and current use in oncology. Cancer Treat Rev 2019; 73: 20-30. [DOI:10.1016/j.ctrv.2018.12.003] [PMID]

3. [3] Faulkner E, Annemans L, Garrison L, Helfand M, Holtorf A-P, Hornberger J, et al. Challenges in the development and reimbursement of personalized medicine-payer and manufacturer perspectives and implications for health economics and outcomes research: a report of the ISPOR Personalized Medicine Special Interest Group. Value Health 2012; 15: 1162-1171. [DOI:10.1016/j.jval.2012.05.006] [PMID]

4. [4] Food UJ. Master protocols: efficient clinical trial design strategies to expedite development of oncology drugs and biologics. Guidance Indust 2018.

5. [5] Redekop WK, Mladsi D. The faces of personalized medicine: a framework for understanding its meaning and scope. Value Health 2013; 16: S4-S9. [DOI:10.1016/j.jval.2013.06.005] [PMID]

6. [6] Groessl EJ, Tally SR, Hillery N, Maciel A, Garces JA. Cost-effectiveness of a pharmacogenetic test to guide treatment for major depressive disorder. J Manag Care Spec Pharm 2018; 24: 726-734. [DOI:10.18553/jmcp.2018.24.8.726] [PMID]

7. [7] Verbelen M, Weale ME, Lewis CM. Cost-effectiveness of pharmacogenetic-guided treatment: are we there yet? Pharmacogenomics J 2017; 17: 395-402. [DOI:10.1038/tpj.2017.21] [PMID] [PMCID]

8. [8]https://www.fda.gov/drugs/science-and-research-drugs/table-pharmacogenomic-biomarkers-drug-labeling.

9. [9] https://www.fda.gov.ir/fa/دارو/فهرست-رسمي-دارويي-کشور.

10. [10] Marques FB, Penedones A, Mendes D, Alves C. A systematic review of observational studies evaluating costs of adverse drug reactions. Clinicoecon Outcomes Res 2016; 8: 413. [DOI:10.2147/CEOR.S115689] [PMID] [PMCID]

11. [11] Collins SL, Carr DF, Pirmohamed M. Advances in the Pharmacogenomics of Adverse Drug Reactions. Drug Safety 2016; 39: 15-27. [DOI:10.1007/s40264-015-0367-8] [PMID]

12. [12] Amin AM, Chin LS, Azri Mohamed Noor D, SK Abdul Kader MA, Kah Hay Y, Ibrahim B. The personalization of clopidogrel antiplatelet therapy: the role of integrative pharmacogenetics and pharmacometabolomics. Cardiol Res Pract 2017; 2017. [DOI:10.1155/2017/8062796] [PMID] [PMCID]

13. [13] Groessl EJ, Tally SR, Hillery N, Maciel A, Garces JA. Cost-effectiveness of a pharmacogenetic test to guide treatment for major depressive disorder. J Manag Care Spec Pharm 2018; 24: 726-734. [DOI:10.18553/jmcp.2018.24.8.726] [PMID]

14. [14] Alagoz O, Durham D, Kasirajan K. Cost-effectiveness of one-time genetic testing to minimize lifetime adverse drug reactions. Pharmacogenomics J 2016; 16: 129-136. [DOI:10.1038/tpj.2015.39] [PMID]

15. [15] Plothner M, Ribbentrop D, Hartman JP, Frank M. Cost-effectiveness of pharmacogenomic and pharmacogenetic test-guided personalized therapies: a systematic review of the approved Active substances for personalized medicine in Germany. Adv Ther 2016; 33: 1461-1480. [DOI:10.1007/s12325-016-0376-8] [PMID] [PMCID]